Molecules to Medicine With Mtor : Translating Critical Pathways into Novel Therapeutic Strategies

Molecules to Medicine with mTOR: Translating Critical Pathways into Novel Therapeutic Strategies is a one-stop reference that thoroughly covers the mechanistic target of rapamycin (mTOR). mTOR, also known as the mammalian target of rapamycin, is a 289-kDa serine/threonine protein kinase that is ubiquitous throughout the body and has a critical role in gene transcription and protein formation, stem cell development, cell survival and senescence, aging, immunity, tissue regeneration and repair, metabolism, tumorigenesis, oxidative stress, and pathways of programmed cell death that include apoptosis and autophagy. Incorporating a translational medicine approach, this important reference highlights the basic cellular biology of mTOR pathways, presents the role of mTOR during normal physiologic function and disease, and illustrates how the mechanisms of mTOR can be targeted for current and future therapeutic treatment strategies. Coverage of mTOR signaling includes the entire life cycle of cells that impacts multiple systems of the body including those of nervous, cardiovascular, immune, musculoskeletal, endocrine, reproductive, renal, and respiratory origin.

• Covers the role of mTOR by internationally recognized expert contributors in the field.
• Provides a clear picture of the complexity of mTOR signaling as well as of the different approaches that could target this pathway at various levels.
• Includes analysis of the role of mTOR and in both health and disease.
• Serves as an important resource for a broad audience of healthcare providers, scientists, drug developers, and students in both clinical and research settings.

Kenneth Maiese, MD, is an internationally recognized physician-scientist whose investigations are designed to translate basic science into successful therapeutic treatments. He maintains therapeutic and scientific expertise in multiple medical disciplines and has been fortunate to receive recognition with outstanding teaching and investigator awards, election to America’s Top Physicians and The Best of U.S. Physicians, recipient of Albert Nelson Marquis Lifetime Achievement Award, and elected as an America’s Health Insurance Plans (AHIP) Executive Leadership Fellow. His work has received the distinction of “High Impact Research and Potential Public Health Benefit” by the National Institutes of Health. As an internationally recognized physician researcher and “C-suite” healthcare leader, he has extensive experience in academic medicine, healthcare delivery, business development, managed care, biotechnology, and drug development holding positions as member and advisor for the National Institutes of Health Biotechnology and Venture Capital Development, National Institutes of Health Innovation Network, Chief Medical Officer, tenured Professor and Chair and Chief of Service of the Department of Neurology and Neurosciences of Rutgers University, Global Head of Translational Medicine and External Innovation, Board Member of the Cancer Institute of New Jersey, Steering Committee Member for the Foundation for the National Institutes of Health, tenured Professor in Neurology, Anatomy & Cell Biology, Molecular Medicine, the Barbara Ann Karmanos Cancer Institute, and the National Institute of Health Center at Wayne State University, and Founding Editor and Editor-in-Chief of multiple highly successful international journals.